Below are the most recent publications written about "Proto-Oncogene Proteins p21(ras)" by people in Profiles.
-
Ye Q, Shvartsbart A, Li Z, Gan P, Policarpo RL, Qi C, Roach JJ, Zhu W, McCammant MS, Hu B, Li G, Yin H, Carlsen P, Hoang G, Zhao L, Susick R, Zhang F, Lai CT, Allali Hassani A, Epling LB, Gallion A, Kurzeja-Lipinski K, Gallagher K, Roman V, Farren MR, Kong W, Deller MC, Zhang G, Covington M, Diamond S, Kim S, Yao W, Sokolsky A, Wang X. Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor. J Med Chem. 2025 Jan 23; 68(2):1924-1939.
-
Chao T, Wang ZX, Bowne WB, Yudkoff CJ, Torjani A, Swaminathan V, Kavanagh TR, Roadarmel A, Sholevar CJ, Cannaday S, Krampitz G, Zhan T, Gorgov E, Nevler A, Lavu H, Yeo CJ, Peiper SC, Jiang W. Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Arch Pathol Lab Med. 2024 12 01; 148(12):1299-1309.
-
Vitello DJ, Shah D, Wells A, Masnyk L, Cox M, Janczewski LM, Abad J, Dawravoo K, D'Souza A, Suh G, Bayer R, Cristofanilli M, Bentrem D, Liu Y, Zhang H, Santana-Santos L, Jennings LJ, Zhang Q, Chawla A. Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy. Ann Surg. 2026 07 01; 284(1):99-107.
-
Francis JH, Silverman RF, Canestraro J, Bossert D, Della Rocca D, Hatzoglou V, Abramson DH, Diamond EL. Histiocytosis of the orbit and its association with KRAS mutations. Blood Adv. 2024 10 08; 8(19):5086-5090.
-
Zhu B, Zhu X, Borland MG, Ralph DH, Chiaro CR, Krausz KW, Ntambi JM, Glick AB, Patterson AD, Perdew GH, Gonzalez FJ, Peters JM. Activation of Peroxisome Proliferator-Activated Receptor-?/d (PPAR?/d) in Keratinocytes by Endogenous Fatty Acids. Biomolecules. 2024 05 21; 14(6).
-
Rodr?guez NA, Patel N, Dariolli R, Ng S, Aleman AG, Gong JQX, Lin HM, Rodr?guez M, Josowitz R, Sol-Church K, Gripp KW, Lin X, Song SC, Fishman GI, Sobie EA, Gelb BD. HRAS-Mutant Cardiomyocyte Model of Multifocal Atrial Tachycardia. Circ Arrhythm Electrophysiol. 2024 04; 17(4):e012022.
-
Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, Chou TF, Roy S, Orban J, Kulkarni P, Salgia R. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
-
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081.
-
Ott CA, Aplin AE. Targeting TEAD-ious resistance. Trends Cancer. 2023 10; 9(10):780-781.
-
Zhou Z, Jia D, Kwon O, Li S, Sun H, Roudier MP, Lin DW, True L, Morrissey C, Creighton CJ, Lee JK, Xin L. Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth. Oncogene. 2023 08; 42(32):2428-2438.